Shareholders to Vote on Significant Equity Plan Expansion Amidst Executive Compensation Scrutiny
IART is trading near its 52-week low of $8.7 (7.0% above the low).
Summary
Integra LifeSciences seeks shareholder approval for a 3.55 million share increase to its equity incentive plan, which could significantly dilute existing shareholders, following a year of substantial net losses and discretionary executive bonuses despite missed performance targets.
Key Events · Corporate Governance and Compliance · IART
-
Proposed Equity Plan Expansion
Shareholders will vote on Amendment No. 3 to the 2003 Equity Incentive Plan, seeking to add 3,550,000 shares for future awards. This represents a potential dilution of approximately 4.56% of current outstanding shares and would increase the total overhang to 14.35%.
-
Executive Bonuses Despite Missed Targets
Despite 2025 performance stock units (PSUs) vesting at 0% due to the company not meeting organic revenue growth goals, the Compensation Committee approved annual cash bonuses for named executive officers at 40% of target, exercising discretion above the 13.3% formulaic funding level.
-
Significant CEO Compensation Amidst Losses
The new CEO, Mojdeh Poul, received total compensation of $9,375,551 in 2025, including a one-time new hire equity grant, in a year where the company reported a net loss of $(516.8) million.
-
Changes to 2026 Equity Compensation Structure
For 2026, the company will replace Restricted Stock Awards (RSAs) with Restricted Stock Units (RSUs) and suspend the use of stock options to reduce share usage. Adjusted EBITDA margin will be added as a second performance metric for PSUs, with maximum vesting increased to 200%.
Analysis · IART · Industrial Applications And Services
This definitive proxy statement outlines key proposals for the upcoming annual meeting, most notably a request to increase the equity incentive plan by 3.55 million shares. This proposed increase, which represents a potential dilution of approximately 4.56% based on current outstanding shares and would bring the total potential overhang to 14.35%, comes after the company reported a substantial net loss of $(516.8) million in 2025. While performance-based equity awards (PSUs) for 2025 vested at 0% due to missed organic revenue growth targets, the Compensation Committee exercised discretion to fund annual cash bonuses for named executive officers at 40% of target, citing contributions to quality systems and retention. The new CEO's 2025 compensation totaled over $9.3 million, including a significant new hire equity grant. Investors will likely scrutinize the request for additional dilutive shares and the executive compensation decisions in light of the company's recent financial performance and ongoing transformation efforts.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 28.9% of the 1666 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IART was trading at $9.31 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $725.6M. The 52-week trading range was $8.70 to $21.34. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.